- AS EVOTEC DRUG SUBSTANCE (GERMANY) GMBH, THE ACQUISITION STRENGTHENS EVOTEC’S CLINICAL AND COMMERCIAL DRUG SUBSTANCE MANUFACTURING CAPACITY AND CAPABILITY ESPECIALLY FOR RARE DISEASES AND PRECISION THERAPEUTICS
Hamburg, Germany, 03 November 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in August 2022, has been completed.
As Evotec Drug Substance (Germany) GmbH (“Evotec DS”), the strategic transaction strengthens Evotec’s clinical and commercial manufacturing capacity and capability for small molecule therapeutics. Located in Halle/Westphalia, Germany, Evotec DS comprises a team of approximately 60 highly skilled chemical manufacturing experts and a fully operational EU cGMP certified facility.
Evotec DS provides a high-quality, European-based solution to Evotec’s partners for the development and commercialisation of drug substances, especially for rare diseases and precision therapeutics. Adding to Evotec’s existing drug substance development and manufacturing platform, the new site will enable the Company to offer its partners highly flexible product lifecycle management strategies. Evotec intends to invest meaningfully in the coming years to establish the facility as a leading European centre of excellence for rare disease drug substance manufacturing.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “The seamless integration of clinical and commercial manufacturing into the drug discovery and development continuum is critical for offering efficient and cost-effective medicinal product development solutions. Within the past few weeks, we have been closely working together with the great team at Evotec DS in order to ensure a smooth and rapid integration of the Halle operation within Evotec; we have been impressed by our new colleagues’ commitment and enthusiasm, and we are thrilled to welcome them into our team dedicated to developing and manufacturing precision medicines to address unmet medical needs, with a strong focus on rare diseases and niche therapeutic indications.”
The contract was signed on 24 August. After meeting obligatory closing conditions, including a long-term lease agreement, the transaction has closed effective 1 November.